Login / Signup

Farnesoid X receptor (FXR) agonist ameliorates systemic insulin resistance, dysregulation of lipid metabolism, and alterations of various organs in a type 2 diabetic kidney animal model.

Sang Youb HanHye Kyoung SongJin Joo ChaJee Young HanYoung Sun KangDae Ryong Cha
Published in: Acta diabetologica (2021)
The FXR agonist improves insulin resistance, renal lipid metabolism, and functional and structural changes in the kidney and other organs.
Keyphrases
  • insulin resistance
  • type diabetes
  • adipose tissue
  • high fat diet
  • metabolic syndrome
  • skeletal muscle
  • polycystic ovary syndrome
  • high fat diet induced
  • fatty acid
  • wound healing